Omega Diagnostics shares: have I missed the boat to invest?

Omega Diagnostics shares have risen in value by more than 100% over the past year, but the company could face headwinds as we advance.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Omega Diagnostics (LSE: ODX) shares have surged in value over the past 12 months. Investors have rushed to buy the testing company’s stock as the business has moved to develop its own coronavirus tests. These efforts have paid off.

At the beginning of February, the company announced that it had inked an agreement with the Department of Health and Social Care to provide manufacturing capacity for Covid-19 lateral flow antigen tests. Today it emerged that this contract could be worth as much as £374m to the organisation

However, this number is just a rough guide at this stage. As Omega warned in its press release, the figure “represents a maximum of the potential value of the contract“.

It also warned that the figure should not be used as an “estimate or forecast of the actual likely value of purchase orders to be received by the company“.

What’s more, at this time, the business has not received confirmation that its Covid-19 lateral flow antigen test “has passed the necessary performance evaluation“. Therefore, “there are no Covid-19 lateral flow antigen tests that can be manufactured by Omega, on behalf of the Government, at this time“.

While this order shows Omega’s potential, it has not guaranteed the organisation’s future. 

Omega Diagnostics shares: challenges ahead 

All of the above explains why Omega Diagnostics shares have hardly reacted to today’s news. This contract could be a massive deal for the firm. Unfortunately, as of yet, it does not have anything to sell.

Further, the contract only presents an opportunity to earn up to £374m. It does not guarantee it. As the UK’s vaccination programme starts to impact infection rates, I think the longer it takes for Omega’s Covid-19 lateral flow antigen test to receive approval, the less likely it is the government will need the entire order. 

I believe that’s the most considerable risk facing the company right now. There’s a lot of expectation baked into the stock price after its recent performance. If Omega can’t sell its tests, I think the stock will quickly deflate. 

On the other hand, if the test is approved and orders are placed up to the total value of the contract, Omega Diagnostics shares could be cheap at current levels.

Is the stock cheap? 

The stock is currently trading with a market capitalisation of £183m. The healthcare industry is trading at an average price-to-sales (P/S) of around four today.

If Omega were to hit its entire contract quota in one year, that implies the stock could command a market value of just under £1.5bn. That’s the bull case here. However, everything would have to go right for that to happen, which, in my opinion, is unlikely. 

I think the group’s chances of making over £300m of sales in one year are slim. With that being the case, I would not buy the stock today. After the recent blowout performance of Omega Diagnostics shares, I think the market is expecting far too much from the company. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »